Durvalumab and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

Ryan, Carrie E.; Lambdin, Jacob; Shah, Shimul A.; Quillin, Ralph C.; Lemon, Kristina; Hernandez, Jonathan M.; Sohal, Davendra

doi:10.1245/s10434-022-12811-7

Cited by 1 publication

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 In this regard, the role of ST as a tool for downstaging, 76 or liver transplantation with TKI did not success and nowadays, a limited but increasing number of publications are reporting the experience of immunotherapy in that field. [77][78][79][80][81][82][83][84] The incorporation of immunotherapy in the setting of adjuvancy 20 Although IMbrave050 20 primarily represents an Asian population, the tumor burden indication aligns with the criteria proposed using the BCLC guidelines for liver resection. 1 In fact, while the study allowed for the inclusion of multifocal HCC cases, 91% of patients in the atezolizumab-bevacizumab cohort who underwent resection had a single lesion.…”

Section: Applicability Into Early Stages: Shaping Disease Trajectoriesmentioning

confidence: 99%

“… 1 In this regard, the role of ST as a tool for downstaging, 76 or liver transplantation with TKI did not success and nowadays, a limited but increasing number of publications are reporting the experience of immunotherapy in that field. 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 The incorporation of immunotherapy in the setting of adjuvancy 20 is much better; IMbrave050 demonstrated that the combination of atezolizumab plus bevacizumab after resection or ablation improves recurrence ‐ free survival in comparison with the active screening of recurrence (HR: 0.72 [95% CI: 0.56–0.93]).…”

Section: Swot Analysis Of Systemic Treatment In Hcc Fieldmentioning

confidence: 99%

See 1 more Smart Citation

Systemic therapies in hepatocellular carcinoma: A revolution?

Fortuny,

Sanduzzi‐Zamparelli,

Reig

2024

UEG Journal

View full text Add to dashboard Cite

The evolution in systemic therapies in hepatocellular carcinoma (HCC) signifies a strategy of high‐cost, high‐gain innovation that originated with sorafenib, despite its limited impact on tumor response. This strategic approach paved the way for the emergence of a second wave of the short‐lived competitive advantage, exemplified by the incorporation of atezolizumab plus bevacizumab and tremelimumab plus durvalumab. In the context of safety concerns within the liver cancer domain, the IMBRAVE150 and HIMALAYA trials boldly incorporated bevacizumab and tremelimumab, respectively, demonstrating the continuation of the high‐risk, high‐reward innovation paradigm. This review delves into the strengths, weaknesses, opportunities, and threats analysis of systemic therapies in the field of HCC.

show abstract

Section: Applicability Into Early Stages: Shaping Disease Trajectoriesmentioning

confidence: 99%

“… 1 In this regard, the role of ST as a tool for downstaging, 76 or liver transplantation with TKI did not success and nowadays, a limited but increasing number of publications are reporting the experience of immunotherapy in that field. 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 The incorporation of immunotherapy in the setting of adjuvancy 20 is much better; IMbrave050 demonstrated that the combination of atezolizumab plus bevacizumab after resection or ablation improves recurrence ‐ free survival in comparison with the active screening of recurrence (HR: 0.72 [95% CI: 0.56–0.93]).…”

Section: Swot Analysis Of Systemic Treatment In Hcc Fieldmentioning

confidence: 99%